Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 6/20 | 0.46 |
| ▸ | RAB9A | P51151 | 6/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.46 |
| ▸ | TP53 | P04637 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | CASP7 | P55210 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25921184 | 0.82 | GAA (0.56) | ALPLGAALMNANPC1RAB9A | |
| SCHEMBL2623137 | 0.82 | NAMPT (0.50) | NPC1RAB9ASMN1; SMN2ALDH1A1ADORA3 | |
| SCHEMBL6933558 | 0.81 | BRD4 (0.63) | ALPLLMNANPC1RAB9ATP53 | |
| SCHEMBL30536136 | 0.81 | BRD4 (0.63) | ALPLLMNANPC1RAB9ATP53 | |
| SCHEMBL16648590 | 0.80 | ALOX15 (0.58) | ALPLGAASMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL1369225 | 0.78 | XDH (0.41) | LMNATSHR | |
| Hydrochloric Acid SCHEMBL1371823 | 0.77 | XDH (0.40) | LMNATSHR | |
| SCHEMBL23123 | 0.77 | BRD4 (0.64) | NPC1RAB9AHSD17B10 | |
| SCHEMBL17778780 | 0.76 | XDH (0.42) | LMNANPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL6463473 | 0.76 | BRD4 (0.60) | NPC1RAB9AADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2862868-B1 | INTERMEDIATE FOR PRODUCTION OF NUCLEOSIDE ANALOGUE, AND METHOD FOR PRODUCING SAME | DAIICHI SANKYO CO LTD (JP) | 2020-04-08 | — | — | EP | disclosed |
| US-9738681-B2 | Intermediate for production of nucleoside analog and method for producing the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-08-22 | — | — | US | disclosed |
| US-20160068561-A9 | Intermediate for Production of Nucleoside Analog and Method for Producing the Same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-03-10 | — | — | US | disclosed |
| US-20150152132-A1 | Intermediate for Production of Nucleoside Analog and Method for Producing the Same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-06-04 | — | — | US | disclosed |
| EP-2862868-A1 | INTERMEDIATE FOR PRODUCTION OF NUCLEOSIDE ANALOGUE, AND METHOD FOR PRODUCING SAME | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-04-22 | — | — | EP | disclosed |
| US-6573045-B1 | Reporter molecule and RNA target molecule, both carrying a fluorescent or chromogenic group, placed in close proximity to each other; addition of test compound inhibits their binding and increases fluorescence; drug screening | RIBOTARGETS, LTD. (GB) | 2003-06-03 | — | — | US | disclosed |
| EP-1144681-A3 | METHODS AND KITS FOR DISCOVERY OF RNA-BINDING COMPOUNDS | RiboTargets Limited (GB) | 2001-11-28 | — | — | EP | disclosed |
| EP-1144681-A2 | METHODS AND KITS FOR DISCOVERY OF RNA-BINDING COMPOUNDS | RiboTargets Limited (GB) | 2001-10-17 | — | — | EP | disclosed |
| WO-1999064625-A2 | METHODS AND KITS FOR DISCOVERY OF RNA-BINDING COMPOUNDS | RIBOTARGETS LIMITED (GB) | 1999-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152132-A1 | Intermediate for Production of Nucleoside Analog and Method for Producing the Same | RNGTT, NSUN2, RNMT | ALPL 770/4885GAA 290/4885LMNA 887/4885 |
| US-20160068561-A9 | Intermediate for Production of Nucleoside Analog and Method for Producing the Same | RNGTT, NSUN2, RNMT | ALPL 770/4885GAA 290/4885LMNA 887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.